The National Institutes of Health (NIH) is urging individuals with long COVID symptoms to participate in clinical trials for potential treatments. These trials aim to alleviate symptoms for the millions of people worldwide who are affected by long COVID. The initial trials will include four potential treatments, with more trials planned in the future to test additional treatments such as drugs, biologics, medical devices, and other therapies.
According to a study conducted by KFF, 15% of all adults in the United States have reported experiencing long COVID symptoms at some point, while 6% currently have symptoms. The impact of long COVID can be significant, with individuals experiencing a range of symptoms, including the loss of taste and smell.
The clinical trials are part of the NIH's Researching COVID to Enhance Recovery (Recover) initiative, which was launched in 2021. This initiative is the largest program worldwide focused on understanding, treating, and preventing long COVID. The trials will target viral persistence, cognitive dysfunction, sleep patterns, autonomic nervous system symptoms, and the inability to exercise and fatigue.
The NIH plans to enroll up to 300 participants in each trial arm and up to 900 participants in larger trials. Interested individuals can find more information about the upcoming trials on the recovercovid.org website.
The NIH emphasizes the importance of clinical trials in finding effective treatments and interventions for long COVID. These trials, along with adequate support and services, access to clinical care, and up-to-date information on long COVID, are part of the comprehensive response to addressing the impact of the condition.
The NIH's efforts are supported by the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare, which contributes to the funding for health and patient safety coverage at USA TODAY. It is important to note that the Masimo Foundation does not have editorial input in the coverage.
By participating in these clinical trials, individuals with long COVID have the opportunity to contribute to the development of effective treatments and potentially find relief from their symptoms. The success of these trials will not only provide hope for those affected by long COVID but also inform future patient care.